Piper Sandler initiates Abbott Laboratories with "overweight" rating, $131 PT
Piper Sandler initiated coverage on Abbott Laboratories (NYSE:ABT) with an "overweight" rating and a price target of $131 per share. Piper Sandler emphasizes Abbott’s attractive valuation, strong financial outlook,
Abbott Laboratories' Best Segment Just Got Even Better: Is the Stock a Buy?
Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes it a top stock to buy and hold for dividend investors -- arguably one of the better ones on the market. There are plenty of reasons to invest in the stock.
Abbott Laboratories stock outperforms competitors despite losses on the day
This was the stock's third consecutive day of losses.
How Does Abbott Laboratories (ABT) Stack Up Against Its Industry Peers?
Abbott Laboratories (ABT) stock saw a decline, ending the day at $114.88 which represents a decrease of $-3.25 or -2.75% from the prior close of $118.13. The stock opened at $117.5 and touched a low of $114.
Calculating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Key Insights The projected fair value for Abbott Laboratories is US$132 based on 2 Stage Free Cash Flow to Equity
Abbott Laboratories stock underperforms Wednesday when compared to competitors
The stock's fall snapped a two-day winning streak.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Wells Fargo Keeps Their Buy Rating on Abbott Laboratories (ABT)
Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Abbott Laboratories (ABT – Research Report) on September 13 and set a
Abbott launches its first over-the-counter continuous glucose monitor in the U.S.
Abbott Laboratories announced Lingo, its first over-the-counter continuous glucose monitor, is available in the U.S.
Abbott Laboratories' Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst
Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech ...
Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change
Cardiovascular disease is rising, and Abbott Laboratories is well-positioned in the CVD treatment space. Read why I'm neutral ...
Piper Sandler Initiates Coverage of Abbott Laboratories (LSE:0Q15) with Overweight Recommendation
Fintel reports that on September 19, 2024, Piper Sandler initiated coverage of Abbott Laboratories ( LSE:0Q15) with a Overweight recommendation. What is the Fund Sentiment?
Buy Rating on Abbott Laboratories: Undervalued with Strong Growth Prospects Despite NEC Litigation
Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...
Yahoo Finance3d
Abbott Laboratories (ABT)
Abbott Laboratories' (NYSE:ABT) stock up by 8.7% over the past three months. Since the market usually pay for a... We recently compiled a list of the Jim Cramer’s Top 10 Stock Picks You Can’t ...
Zacks.com on MSN4d
Abbott Stock Hurt by Macroeconomic Issues & FX Headwind
Foreign exchange fluctuation is a major headwind for ABT, as a considerable percentage of its revenues comes from outside the ...
drugdeliverybusiness5d
Class action suit targets Abbott FreeStyle Libre amid claims of data sharing
Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...